HDAC6 and head and neck squamous cell carcinoma: At the same time, the combination of bortezomib and the histone deacetylase inhibitor trichostatin inhibited HDAC6 activity, reduced autophagy induction, and significantly enhanced bortezomib-induced apoptosis of HNSCC cells.